VivoSeq
Oncology

Solid Cancers

0

Pipeline Programs↗

4

Active Trials↗

3

Companies Involved↗

Solid Cancers is an early-stage landscape with 0 programs across 3 companies. The most active players are Bristol-Myers Squibb, Regeneron, Boehringer Ingelheim.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalRegeneron logo

Regeneron

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed5 · 50%
Recruiting3 · 30%
Terminated1 · 10%
Enrolling by invitation1 · 10%

Clinical Trials

Trial Activity

10 trials

A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers
Recruiting·LLight Chain Bioscience - Novimmune SA·Phase 1·NCT05403554·70 enrolled
A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab
Recruiting·Regeneron logoRegeneron·Phase 1·NCT05259709·50 enrolled
MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers
Recruiting·MMayo Clinic·Phase 1·NCT06911008·42 enrolled
A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers
Enrolling by invitation·—·Phase 1/2·NCT00900497·29 enrolled
Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT00969553·59 enrolled
An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1/2·NCT02598960·295 enrolled
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®
Completed·OOncovir, Inc.·Phase 2·NCT02423863·26 enrolled
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1/2·NCT02737475·166 enrolled
ACTolog in Patients With Solid Cancers
Completed·IImmatics US, Inc.·Phase 1·NCT02876510·38 enrolled
Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies
Terminated·UUniversity of Chicago·Phase 1·NCT01705106·21 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)